Who Should Take Rybelsus?

Understanding Rybelsus and Its Approved Uses

Rybelsus (semaglutide) is an oral GLP-1 receptor agonist approved by the FDA for two primary indications. First, it serves as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. Second, it reduces the risk of major cardiovascular events like heart attack and stroke in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

Primary Candidates for Rybelsus Treatment

Adults with Type 2 Diabetes

The most straightforward answer to who should take Rybelsus centers on adults diagnosed with type 2 diabetes. Healthcare providers typically consider this medication when patients need additional blood sugar control beyond what diet, exercise, and first-line medications like metformin can achieve. However, it may also be used first-line, according to new treatment guidelines.

Rybelsus works by mimicking a hormone called GLP-1 that your body naturally produces after eating. This hormone helps regulate blood sugar by stimulating insulin release when glucose levels are elevated and slowing digestion to prevent blood sugar spikes.

Patients with Cardiovascular Risk Factors

Adults with type 2 diabetes who have additional cardiovascular risk factors represent another key group who should consider Rybelsus. The medication has demonstrated benefits in reducing major adverse cardiovascular events, making it particularly valuable for patients with established heart disease, a history of stroke, or multiple risk factors like high blood pressure, high cholesterol, or smoking history.

Healthcare providers evaluate cardiovascular risk through various factors, including age, family history, blood pressure readings, cholesterol levels, and lifestyle factors. Patients with elevated risk may benefit from Rybelsus even if their diabetes is relatively well-controlled with other medications.

Who Should Not Take Rybelsus

Absolute Contraindications

Certain individuals should never take Rybelsus due to safety concerns identified in clinical trials. These absolute contraindications include people with a personal or family history of medullary thyroid carcinoma, patients with Multiple Endocrine Neoplasia syndrome type 2, and individuals who have experienced serious allergic reactions to semaglutide or any ingredients in Rybelsus.

The thyroid cancer restriction stems from animal studies showing thyroid tumors in rodents exposed to semaglutide. While the relevance to humans remains unclear, regulatory agencies maintain this precaution as a safety measure.

Type 1 Diabetes Exclusion

People with type 1 diabetes should not take Rybelsus. This autoimmune condition requires insulin replacement therapy because the pancreas produces little to no insulin. Rybelsus works by enhancing the body’s existing insulin production and would not provide adequate treatment for type 1 diabetes.

Additionally, Rybelsus has not been studied in children under 18 years of age, so pediatric use is not recommended regardless of diabetes type.

Special Considerations and Monitoring Requirements

Kidney Function Assessment

Patients with kidney problems require careful evaluation before starting Rybelsus. The medication can potentially worsen kidney function, particularly in people who become dehydrated from gastrointestinal side effects like nausea, vomiting, or diarrhea. Healthcare providers typically check kidney function through blood tests before prescribing Rybelsus and monitor it regularly during treatment.

History of Pancreatitis

Individuals with a history of pancreatitis need special consideration when determining if they should take Rybelsus. While not an absolute contraindication, previous pancreatic inflammation increases the risk of recurrence with GLP-1 medications. Healthcare providers weigh the benefits against potential risks and may recommend alternative treatments.

Diabetic Retinopathy Considerations

Patients with diabetic eye disease require close monitoring when starting Rybelsus. Rapid improvements in blood sugar control can sometimes worsen diabetic retinopathy in the short term. Eye care specialists may need to evaluate and monitor patients with existing retinopathy more frequently during the initial months of treatment.

Practical Factors Affecting Candidacy

Ability to Follow Administration Requirements

Rybelsus requires specific administration instructions that not all patients can follow consistently. The medication must be taken on an empty stomach with no more than four ounces of water, and patients must wait at least 30 minutes before eating, drinking, or taking other medications. Individuals with irregular schedules, cognitive impairment, or difficulty adhering to medication routines may not be ideal candidates.

Tolerance for Gastrointestinal Side Effects

Most patients experience some degree of nausea, particularly when starting Rybelsus or increasing the dose. People with sensitive stomachs, a history of eating disorders, or those who cannot tolerate nausea for any reason may need alternative treatments. Healthcare providers typically start with the lowest dose and increase gradually to minimize these effects.

Role in Diabetes Treatment Plans

First-Line Therapy Positioning

GLP-1s like Rybelsus are now recommended as first-line therapy for type 2 diabetes. However, some healthcare providers may prefer starting with metformin due to its established safety profile, effectiveness, and lower cost.

Combination with Other Diabetes Medications

Many patients who should take Rybelsus will use it alongside other diabetes medications. It combines well with metformin, SGLT-2 inhibitors, and insulin. However, combining Rybelsus with other medications that can cause low blood sugar, such as insulin or sulfonylureas, increases hypoglycemia risk and requires dose adjustments and careful monitoring.

Cost and Accessibility Considerations

The decision of who should take Rybelsus also involves practical considerations around cost and insurance coverage. Brand-name medications like Rybelsus typically cost significantly more than generic alternatives. Patients should discuss affordability concerns with their healthcare providers and explore options for reducing medication costs.

For patients seeking more affordable access to diabetes medications, exploring cash-pay options through reliable pharmacy services like Universal Drugstore can provide cost-effective alternatives to traditional insurance-based pricing. These services often offer significant savings compared to standard retail pharmacy prices.

Working with Healthcare Providers

Determining who should take Rybelsus ultimately requires individualized medical assessment. Healthcare providers consider multiple factors, including diabetes control, cardiovascular risk, kidney function, other health conditions, medication tolerance, and patient preferences. The decision-making process typically involves trying other medications first and evaluating their effectiveness before considering Rybelsus.

Patients should have open discussions with their healthcare team about treatment goals, lifestyle factors, and any concerns about potential side effects. Regular monitoring allows providers to assess whether Rybelsus continues to be appropriate and effective for each individual patient.

The ideal candidate for Rybelsus is an adult with type 2 diabetes who needs additional blood sugar control or cardiovascular risk reduction, can follow the specific administration requirements, and has been evaluated for contraindications and risk factors. However, each patient’s situation is unique, making personalized medical evaluation essential for determining appropriateness.

References

• Rybelsus (semaglutide) tablets, for oral use [prescribing information]. Novo Nordisk. DailyMed. Last updated 12/2025. Accessed June 28, 2026.
• What to Expect with Rybelsus. Novo Nordisk. Accessed June 28, 2026.
• Rybelsus Patient Brochure. Novo Nordisk. Accessed June 28, 2026.
• Rybelsus (Semaglutide). WebMD. Accessed June 28, 2026.